Adult Pulmonary Vascular Disease

Repair of Sinus Venosus Atrial Septal Defect in 2 Patients With Severe Pulmonary Arterial Hypertension

Ryo Sakuma, Gareth Morgan, Elizabeth Yeung, Benjamin S. Frank, Charles Simpkin, Dunbar IvyUniversity of Colorado School of Medicine.United States Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70285 AbstractPretreatment with targeted pulmonary arterial hypertension (PAH) therapy in adults with unrepaired atrial septal defects (ASDs) has been increasingly reported as a means to improve pulmonary hemodynamics and expand candidacy […]

Repair of Sinus Venosus Atrial Septal Defect in 2 Patients With Severe Pulmonary Arterial Hypertension Read More »

Safety and Efficacy of a Novel Atrial Flow Regulator in Patients With Severe Pulmonary Arterial Hypertension: The AFR-Prophet Study

Jozef Bartunek, Emiliano Fiori, Grzegorz Kopec, Teoman Kilic, Joseph Pattathu, Nikolaus A. HaasAZORG, Sapienza University. University Medical College and John Paul II Hospital in Krakow. Kocaeli University. Ludwig-Maximilians-University Munich.Belgium, Italy, Poland, Turkey and Germany Journal of the Society of Cardiovascular Angiography and InterventionsJ Soc Cardiovasc Angiogr Interv 2026; DOI: 10.1016/j.jscai.2026.104390 AbstractBackground: Pulmonary arterial hypertension (PAH) is a

Safety and Efficacy of a Novel Atrial Flow Regulator in Patients With Severe Pulmonary Arterial Hypertension: The AFR-Prophet Study Read More »

Refining the Definition for “Low Risk” in Pulmonary Arterial Hypertension: Time to Reduce Morbidity and Mortality

Charles Fauvel, Priscilla Correa Jaque, Yongqi Liu, Sang Wan Lee, Sandeep Sahay, Nelson A. Villasmil Hernandez, Jason Weatherald, James White, Allen Everett, Megan Griffith, Thomas M. Cascino, Adam Perer, Katelyn Morrison, Michael Lewis, Yuri Matusov, Shili Lin, Raymond L. BenzaRouen University Hospital and French National Institute for Health and Medical Research. Eastern Virginia Medical School,

Refining the Definition for “Low Risk” in Pulmonary Arterial Hypertension: Time to Reduce Morbidity and Mortality Read More »

The Role of the Cellular Communication Network Protein Family in Pulmonary Arterial Hypertension

Carly E. Byrd, Jennifer E. Schramm, Jun Yang, Allan E. Barnes, Megan Griffiths, William C. Nichols, David D. Ivy, Eric D. Austin, Allen D. EverettJohns Hopkins University. University of Texas Southwestern. Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine. Children’s Hospital Colorado. Vanderbilt University Medical Center. United States Pulmonary CirculationPulm Circ

The Role of the Cellular Communication Network Protein Family in Pulmonary Arterial Hypertension Read More »

Lactobacillus Is Associated With Disease in Pulmonary Arterial Hypertension: A Prospective Cohort Study

Arun Jose, Senu Apewokin, Nicholas J. Ollberding, Qing Duan, Jennifer Trannguyen, Sasha Z. Prisco, Thenappan Thenappan, Anna R. Hemnes, Jean M. ElwinUniversity of Cincinnati and Cincinnati Children’s Hospital Medical Center. University of Minnesota. Vanderbilt University.United States Comprehensive PhysiologyComp Physiol 2026; 16: DOI: 10.1002/cph4.70161 AbstractBackground: Gut dysbiosis and gut-derived metabolites have been linked to pulmonary arterial hypertension. However,

Lactobacillus Is Associated With Disease in Pulmonary Arterial Hypertension: A Prospective Cohort Study Read More »

Metabolomics of Right Ventricular Function in Pulmonary Hypertension

Jonathan Chacon-Barahona, Samuel J Chung, Jonah D Garry, Robert Frantz, Franz Rischard, Paul M Hassoun, Stephen C Mathai, Catherine E Simpson, Gerald Beck, Nicholas S Hill, Jane A Leopold, Aaron B Waxman, Erika B Rosenzweig, Barry A Borlaug, Monica Mukherjee, Rebecca Vanderpool, Miriam Jacob, Reena Mehra, Margaret M Park, J Emanuel Finet, Samar Farha, Gabriele Grunig, Deborah Kwon, Suzy Comhair, Serpil Erzurum, John Barnard, Bo Hu, Christine L Jellis, Alexandra Christin Racanelli, Jan Krumsiek, Evan L Brittain, Anna Hemnes, Evelyn Horn; PVDOMICS Study GroupWeill Cornell Medical College. Albert

Metabolomics of Right Ventricular Function in Pulmonary Hypertension Read More »

Transcatheter closure of anomalous systemic arterial supply to the left lung from the left subclavian artery: Diagnostic and procedural challenges

Anil Kumar Singhi, Manojit Lodha, Santunu De, Arpita Choraria, Sandip Sardar, Ejaz Ahmed Bari, Debadri ChakrabartiManipal Hospital EM Bypass. Vivekananda Institute of Medical Sciences. India Journal of Cardiology CasesJ Cardiol Cases 2025 Aug 5; 32: 207-210DOI: 10.1016/j.jccase.2025.07.007 AbstractA 26-year-old woman with chronic effort intolerance and a continuous murmur underwent evaluation for suspected congenital heart disease. While

Transcatheter closure of anomalous systemic arterial supply to the left lung from the left subclavian artery: Diagnostic and procedural challenges Read More »

Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atrial septal defect, ventricular septal defect or patent ductus arteriosus), including Eisenmenger syndrome: the SuMILE trial

Keimei Yoshida, Kazuya Hosokawa, Takahiro Hiraide, Satoshi Akagi, Kentaro Ejiri, Yu Taniguchi, Shiro Adachi, Takumi Inami, Naohiko Nakanishi, Masaharu Kataoka, Taijyu Satoh, Shunsuke Tatebe, Toshiro Shinke, Hideshi Tomita, Yusuke Akazawa, Takashi Higaki, Koshiro Tagawa, Ayako Ishikita, Soshun Asakawa, Kohtaro AbeKyushu University and Kyushu University Hospital. Keio University School of Medicine. Okayama University. Kobe University Hospital.

Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atrial septal defect, ventricular septal defect or patent ductus arteriosus), including Eisenmenger syndrome: the SuMILE trial Read More »

Sotatercept in Patients With Eisenmenger Syndrome

Oktay Tutarel, Oliver Miera, Felix BergerDeutsches Herzzentrum der Charité, Freie Universität Berlin and Humboldt-Universität zu Berlin.Germany Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70283 AbstractEisenmenger syndrome represents a complex and severe form of pulmonary arterial hypertension (PAH) associated with congenital heart disease. Sotatercept, a first-in-class activin-signaling inhibitor, offers a novel therapeutic approach in the treatment of PAH,

Sotatercept in Patients With Eisenmenger Syndrome Read More »

Effects of altitude and exercise on pulmonary capillary integrity: evidence for subclinical high-altitude pulmonary edema

Marlowe W. Eldridge, Ruedi K. Braun, Ken Y. Yoneda, William F. WalbyUniversity of Wisconsin.United States Journal of Applied PhysiologyJ Appl Physiol 2006; 100: 972-980 DOI: 10.1152/japplphysiol.01048.2005 AbstractStrenuous exercise may be a significant contributing factor for development of high-altitude pulmonary edema, particularly at low or moderate altitudes. Thus we investigated the effects of heavy cycle ergometer exercise (90%

Effects of altitude and exercise on pulmonary capillary integrity: evidence for subclinical high-altitude pulmonary edema Read More »

Scroll to Top